Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

21. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.

Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. Importance: Most cognitive functions decline with age. Prior studies suggest that testosterone treatment may improve these functions. Objective: To determine if testosterone treatment compared with placebo is associated with improved verbal memory and other cognitive functions in older men with low testosterone and age-associated memory impairment (AAMI). Design, Setting (...) , and Participants: The Testosterone Trials (TTrials) were 7 trials to assess the efficacy of testosterone treatment in older men with low testosterone levels. The Cognitive Function Trial evaluated cognitive function in all TTrials participants. In 12 US academic medical centers, 788 men who were 65 years or older with a serum testosterone level less than 275 ng/mL and impaired sexual function, physical function, or vitality were allocated to testosterone treatment (n = 394) or placebo (n = 394). A subgroup

JAMA2017 Full Text: Link to full Text with Trip Pro

22. Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines

Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Published on: February 9, 2017 Project Number: RA0892-000 Product Line: Research Type: Drug Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of testosterone for patients with depression? What is the clinical effectiveness of testosterone for patients with post-traumatic stress disorder? What is the clinical effectiveness of testosterone for patients with fibromyalgia? What are the evidence-based guidelines for the use of testosterone for patients with depression, PTSD, or fibromyalgia? Key Message Two systematic reviews, two randomized controlled trials

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

23. Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)

Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) 29264442 2018 11 13 2472-1972 1 1 2017 Jan 01 Journal of the Endocrine Society J Endocr Soc Distribution of Salivary Testosterone in Men and Women in a British General Population-Based Sample: The Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). 14-25 10.1210/js.2016-1029 Measurement of salivary (...) testosterone (Sal-T) to assess androgen status offers important potential advantages in epidemiological research. The utility of the method depends on the interpretation of the results against robustly determined population distributions, which are currently lacking. To determine age-specific Sal-T population distributions for men and women. Morning saliva samples were obtained from participants in the third National Survey of Sexual Attitudes and Lifestyles, a probability sample survey of the British

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

26. Testosterone treatment and risk of venous thromboembolism: population based case-control study.

Testosterone treatment and risk of venous thromboembolism: population based case-control study. OBJECTIVE: To determine the risk of venous thromboembolism associated with use of testosterone treatment in men, focusing particularly on the timing of the risk. DESIGN: Population based case-control study SETTING: 370 general practices in UK primary care with linked hospital discharge diagnoses and in-hospital procedures and information on all cause mortality. PARTICIPANTS: 19 215 patients (...) with confirmed venous thromboembolism (comprising deep venous thrombosis and pulmonary embolism) and 909 530 age matched controls from source population including more than 2.22 million men between January 2001 and May 2013. EXPOSURE OF INTEREST: Three mutually exclusive testosterone exposure groups were identified: current treatment, recent (but not current) treatment, and no treatment in the previous two years. Current treatment was subdivided into duration of more or less than six months. MAIN OUTCOME

BMJ2016 Full Text: Link to full Text with Trip Pro

27. Testosterone Therapy Among Prostate Cancer Survivors

Testosterone Therapy Among Prostate Cancer Survivors 27474995 2018 09 27 2018 11 13 2050-0521 4 4 2016 10 Sexual medicine reviews Sex Med Rev Testosterone Therapy Among Prostate Cancer Survivors. 376-88 10.1016/j.sxmr.2016.06.005 S2050-0521(16)30026-9 The use of testosterone in men with a history of prostate cancer remains controversial in light of established findings linking androgens to prostate cancer growth. However, hypogonadism significantly affects quality of life and has negative (...) sequelae, and the risks and benefits of testosterone therapy might be worthwhile to consider in all men, even those with a history of high-risk prostate cancer. To discuss the effects of testosterone on the prostate and the use of testosterone therapy in hypogonadal men with a history of prostate cancer. Review of the literature examining the effects of testosterone on the prostate and the efficacy and safety of exogenous testosterone in men with a history of prostate cancer. Summary of effects

Sexual medicine reviews2016 Full Text: Link to full Text with Trip Pro

28. Is Testosterone Detrimental to Renal Function?

Is Testosterone Detrimental to Renal Function? 29318206 2018 11 13 2468-0249 1 4 2016 Nov Kidney international reports Kidney Int Rep Is Testosterone Detrimental to Renal Function? 306-310 10.1016/j.ekir.2016.07.004 Filler Guido G Department of Paediatrics, Children's Hospital at London Health Science Centre, London, Ontario, Canada. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada. Department of Medicine, University of Western Ontario

Kidney international reports2016 Full Text: Link to full Text with Trip Pro

29. Testosterone Treatment in Older Men.

Testosterone Treatment in Older Men. Testosterone Treatment in Older Men. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406354 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):90. doi: 10.1056/NEJMc1603665. Testosterone Treatment in Older Men. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27406354 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substance Full Text Sources Medical Miscellaneous PubMed Commons 0

NEJM2016

30. Testosterone Treatment in Older Men.

Testosterone Treatment in Older Men. Testosterone Treatment in Older Men. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406355 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):88. doi: 10.1056/NEJMc1603665#SA1. Testosterone Treatment in Older Men. 1 . 1 Boston University School of Medicine, Boston, MA thperls@bu.edu. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406355 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text Sources Medical Miscellaneous PubMed Commons

NEJM2016 Full Text: Link to full Text with Trip Pro

31. Testosterone Treatment in Older Men.

Testosterone Treatment in Older Men. Testosterone Treatment in Older Men. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406356 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):88-9. doi: 10.1056/NEJMc1603665#SA2. Testosterone Treatment in Older Men. 1 , 1 , 1 . 1 Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406356 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text Sources

NEJM2016 Full Text: Link to full Text with Trip Pro

32. Testosterone Treatment in Older Men.

Testosterone Treatment in Older Men. Testosterone Treatment in Older Men. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406357 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):89. doi: 10.1056/NEJMc1603665#SA3. Testosterone Treatment in Older Men. 1 , 2 , 3 . 1 Brigham and Women's Hospital, Boston, MA dmata@bwh.harvard.edu. 2 University of Miami Miller School of Medicine, Miami, FL. 3 Baylor College of Medicine, Houston, TX. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406357 DOI

NEJM2016 Full Text: Link to full Text with Trip Pro

33. Testosterone Treatment in Older Men.

Testosterone Treatment in Older Men. Testosterone Treatment in Older Men. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406358 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):89-90. doi: 10.1056/NEJMc1603665#SA4. Testosterone Treatment in Older Men. 1 , 1 , 1 . 1 KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406358 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text Sources Medical Miscellaneous PubMed

NEJM2016 Full Text: Link to full Text with Trip Pro

34. Establishing a Framework - Does Testosterone Supplementation Help Older Men?

Establishing a Framework - Does Testosterone Supplementation Help Older Men? Establishing a Framework--Does Testosterone Supplementation Help Older Men? - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26886526 (...) Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Feb 18;374(7):682-3. doi: 10.1056/NEJMe1600196. Establishing a Framework--Does Testosterone Supplementation Help Older Men? 1 . 1 From the Department of Medicine, Oregon Health and Science University, Portland. Comment on [N Engl J Med. 2016] PMID: 26886526 DOI: [Indexed

NEJM2016

35. It’s time to reconsider early-morning testosterone tests

It’s time to reconsider early-morning testosterone tests It's time to reconsider early-morning testosterone tests Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics It's time to reconsider early-morning testosterone tests View/ Open Date 2015-07 Format Metadata Abstract Guidelines recommend collecting an early-morning (...) sample to compensate for the natural diurnal variation in testosterone levels. But for men 45 and older, this is unnecessary. Practice changer: Early-morning testosterone tests are necessary only for men younger than age 45. Because the natural diurnal variation in testosterone levels tends to diminish with age, it is acceptable to test men ages 45 and older before 2 pm.1 URI Part of Citation Journal of Family Practice, 64(7) 2015: 418-419. Collections hosted by hosted by

PURLS2016

36. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline

Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline Guidelines CMAJ ©2015 8872147 Canada Inc. or its licensors CMAJ 1 CME T estosterone deficiency syndrome, also known as late-onset hypogonadism, is a clinical and biochemical syndrome that can occur in men in association with advancing age. The condition is characterized by deficient testicular production of testosterone. It may affect multiple organ systems and can result in substantial health (...) consequences. 1 The management of testosterone deficiency syndrome in men is associated with much contro- versy, creating confusion and reluctance among health practitioners in dealing with the subject. A small number of professional bodies 2,3 have pub- lished guidelines on the topic, yet a multidisci- plinary guideline with specific Can adian content did not exist. This is relevant because there are important differences in health care systems com- pared with other jurisdictions in North America

CMA Infobase (Canada)2015

37. It’s time to reconsider early-morning testosterone tests

It’s time to reconsider early-morning testosterone tests It's time to reconsider early-morning testosterone tests Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics It's time to reconsider early-morning testosterone tests View/ Open Date 2015-07 Format Metadata Abstract Guidelines recommend collecting an early-morning (...) sample to compensate for the natural diurnal variation in testosterone levels. But for men 45 and older, this is unnecessary. Practice changer: Early-morning testosterone tests are necessary only for men younger than age 45. Because the natural diurnal variation in testosterone levels tends to diminish with age, it is acceptable to test men ages 45 and older before 2 pm.1 URI Part of Citation Journal of Family Practice, 64(7) 2015: 418-419. Collections hosted by hosted by

PURLS2015

38. Testosterone and "Age-Related Hypogonadism" - FDA Concerns.

Testosterone and "Age-Related Hypogonadism" - FDA Concerns. Testosterone and "Age-Related Hypogonadism"--FDA Concerns. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26287846 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Aug 20;373(8):689-91. doi: 10.1056/NEJMp1506632. Testosterone and "Age-Related Hypogonadism"--FDA Concerns. 1 , , , , , . 1 From the Food and Drug Administration, Silver Spring, MD. PMID: 26287846 DOI: [Indexed for MEDLINE] MeSH terms Substance Full Text Sources Miscellaneous PubMed Commons 0 comments How to cite

NEJM2015

39. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial.

Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. 26262795 2015 08 12 2015 08 19 2016 10 17 1538-3598 314 6 2015 Aug 11 JAMA JAMA Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. 570-81 10.1001/jama.2015.8881 Testosterone use in older men (...) is increasing, but its long-term effects on progression of atherosclerosis are unknown. To determine the effect of testosterone administration on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels. Testosterone's Effects on Atherosclerosis Progression in Aging Men (TEAAM) was a placebo-controlled, double-blind, parallel-group randomized trial involving 308 men 60 years or older with low or low-normal testosterone levels (100-400 ng/dL; free testosterone <50 pg/mL

JAMA2015 Full Text: Link to full Text with Trip Pro

40. Comparative Safety of Testosterone Dosage Forms

Comparative Safety of Testosterone Dosage Forms 25962056 2015 07 07 2015 09 25 2017 02 20 2168-6114 175 7 2015 Jul JAMA internal medicine JAMA Intern Med Comparative Safety of Testosterone Dosage Forms. 1187-96 10.1001/jamainternmed.2015.1573 Increases in testosterone use and mixed reports of adverse events have raised concerns about the cardiovascular safety of testosterone. Testosterone is available in several delivery mechanisms with varying pharmacokinetics; injections cause spikes (...) in testosterone levels, and transdermal patches and gels cause more subtle but sustained increases. The comparative cardiovascular safety of gels, injections, and patches has not been studied. To determine the comparative cardiovascular safety of testosterone injections, patches, and gels. A retrospective cohort study was conducted using administrative claims from a commercially insured (January 1, 2000, to December 31, 2012) and Medicare (January 1, 2007, to December 31, 2010) population in the United States

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro